CRDL
Cardiol TherapeuticsCRDL
CRDL
About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Employees: 17
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
3,660% more call options, than puts
Call options by funds: $188K | Put options by funds: $5K
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
3% more funds holding
Funds holding: 40 [Q3] → 41 (+1) [Q4]
2.05% more ownership
Funds ownership: 7.12% [Q3] → 9.17% (+2.05%) [Q4]
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
3% less capital invested
Capital invested by funds: $9.86M [Q3] → $9.59M (-$270K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9
806%
upside
Avg. target
$9
806%
upside
High target
$9
806%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Vernon Bernardino 24% 1-year accuracy 16 / 67 met price target | 806%upside $9 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion
Neutral
Newsfile Corp
3 weeks ago
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST. A replay of the live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Positive
Proactive Investors
1 month ago
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new research published in the Journal of the American College of Cardiology: Basic to Translational Science (JACBTS) supports the potential of its cannabidiol-based drug candidate CRD-38 to treat heart failure. The study, conducted by scientists at Tecnológico de Monterrey in collaboration with researchers from the DeBakey Heart and Vascular Center in Houston, found that pharmaceutically manufactured cannabidiol, administered subcutaneously, helped preserve mitochondrial function and calcium handling in a preclinical model of heart failure.
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.org/doi/abs/10.1016/j.jacbts.2024.12.009). This research was conducted by scientists from Tecnológico de Monterrey who, together with researchers from the DeBakey Heart and Vascular Center in Houston, TX, are collaborating with Cardiol on the development of the Company's proprietary subcutaneous ("SubQ") formulation of cannabidiol, CRD-38, to treat heart failure with preserved ejection fraction.
Positive
Seeking Alpha
1 month ago
Cardiol Therapeutics: Bargain Stock Price With Share Price Appreciation Catalysts
Cardiol Therapeutics' CardiolRx™ shows promise in treating heart conditions, with ongoing clinical trials for pericarditis, myocarditis, and heart failure, and orphan drug status boosting its potential. Despite a 40% stock price decline, the market undervalues Cardiol's pipeline, with upcoming trial data and potential partnerships as catalysts for appreciation. The company is well-funded, with $15.9 million in cash reported as of 9/30/24, sufficient to meet milestones into 2026, and has a market cap of $99 million.
Neutral
Newsfile Corp
1 month ago
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST. A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Cardiol website (www.cardiolrx.com/investors/events-presentations/).
Neutral
Zacks Investment Research
1 month ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Neutral
GlobeNewsWire
3 months ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics President and CEO, David Elsley, who discusses the company's lead oral drug, CardiolRx™, which is entering a late-stage Phase III clinical trial, MAVERIC, for patients with recurrent pericarditis who are at high risk for recurrence. Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease.
Neutral
MarketBeat
3 months ago
3 Penny Stocks Ready to Break Out in 2025
Known for their uncommonly pronounced risk/reward profile, penny stocks all too often entice investors with their low prices and potential for significant returns, only to fail to live up to those expectations. The world of penny stocks is also characterized by pump-and-dump and other scams, facilitated by the fact that most penny stock companies do not have an extensive history of financial reporting or an established brand name and presence.
Positive
Proactive Investors
4 months ago
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced encouraging results from its Phase II MAvERIC-Pilot study, showcasing the sustained efficacy of its anti-inflammatory therapy, CardiolRx, in treating symptomatic recurrent pericarditis. The findings, which were presented at the American Heart Association Scientific Sessions 2024, highlighted marked improvements in pericarditis pain and inflammation, with benefits persisting throughout the 26-week trial.
Neutral
Newsfile Corp
4 months ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week study Episodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trials Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis. The data showed that the marked improvements in both pericarditis pain and inflammation, previously reported at the 8-week primary endpoint, were maintained throughout the extension period of the 26-week study.
Charts implemented using Lightweight Charts™